Host recognition and target differentiation by factor H, a regulator of the alternative pathway of complement.

[1]  J. Weiler,et al.  Control of the amplification convertase of complement by the plasma protein beta1H. , 1976, Proceedings of the National Academy of Sciences of the United States of America.

[2]  K. Whaley,et al.  Modulation of the alternative complement pathways by beta 1 H globulin , 1976, The Journal of experimental medicine.

[3]  D. Fearon,et al.  Activation of the alternative complement pathway due to resistance of zymosan-bound amplification convertase to endogenous regulatory mechanisms. , 1977, Proceedings of the National Academy of Sciences of the United States of America.

[4]  K. Austen,et al.  Activation of the alternative complement pathway with rabbit erythrocytes by circumvention of the regulatory action of endogenous control proteins , 1977, The Journal of experimental medicine.

[5]  R. Schreiber,et al.  Human complement C3b inactivator: isolation, characterization, and demonstration of an absolute requirement for the serum protein beta1H for cleavage of C3b and C4b in solution , 1977, The Journal of experimental medicine.

[6]  D. Fearon.  Regulation by membrane sialic acid of beta1H-dependent decay-dissociation of amplification C3 convertase of the alternative complement pathway. , 1978, Proceedings of the National Academy of Sciences of the United States of America.

[7]  M. Pangburn,et al.  Complement C3 convertase: cell surface restriction of beta1H control and generation of restriction on neuraminidase-treated cells. , 1978, Proceedings of the National Academy of Sciences of the United States of America.

[8]  D. Fearon,et al.  Regulation of the amplification C3 convertase of human complement by an inhibitory protein isolated from human erythrocyte membrane. , 1979, Proceedings of the National Academy of Sciences of the United States of America.

[9]  R. Schreiber,et al.  Raji cell injury and subsequent lysis by the purified cytolytic alternative pathway of human complement. , 1980, Clinical immunology and immunopathology.

[10]  Robert B Sim,et al.  Purification and structural studies on the complement-system control protein beta 1H (Factor H). , 1982, The Biochemical journal.

[11]  D. Fearon,et al.  Isolation of a human erythrocyte membrane glycoprotein with decay-accelerating activity for C3 convertases of the complement system. , 1982, Journal of immunology.

[12]  J. Lambris,et al.  Characterization of the lymphocyte membrane receptor for factor H (β1H- globulin) with an antibody to anti-factor H idiotype , 1982, The Journal of experimental medicine.

[13]  R. Hirsch,et al.  Natural immunity to Sindbis virus is influenced by host tissue sialic acid content. , 1983, Proceedings of the National Academy of Sciences of the United States of America.

[14]  M. Kazatchkine,et al.  Lysine residues, but not carbohydrates, are required for the regulatory function of H on the amplification C3 convertase of complement. , 1984, Journal of immunology.

[15]  John D Lambris,et al.  Localization of the complement-component-C3b-binding site and the cofactor activity for factor I in the 38kDa tryptic fragment of factor H. , 1984, The Biochemical journal.

[16]  J. Lambris,et al.  Structural and functional analysis of the complement component factor H with the use of different enzymes and monoclonal antibodies to factor H. , 1985, The Biochemical journal.

[17]  M. Pangburn,et al.  Species specificity of recognition by the alternative pathway of complement. , 1985, Journal of immunology.

[18]  M. Gubler,et al.  H deficiency in two brothers with atypical dense intramembranous deposit disease. , 1986, Kidney international.

[19]  J. Atkinson,et al.  Purification and characterization of a membrane protein (gp45-70) that is a cofactor for cleavage of C3b and C4b , 1986, The Journal of experimental medicine.

[20]  B. Tack,et al.  Murine protein H is comprised of 20 repeating units, 61 amino acids in length. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[21]  M. Pangburn,et al.  The C3 convertase of the alternative pathway of human complement. Enzymic properties of the bimolecular proteinase. , 1986, The Biochemical journal.

[22]  Robert B Sim,et al.  Complement factor H-binding protein of Raji cells and tonsil B lymphocytes. , 1987, The Biochemical journal.

[23]  G. Jarvis,et al.  Sialic acid of group B Neisseria meningitidis regulates alternative complement pathway activation , 1987, Infection and immunity.

[24]  G. Nemerow,et al.  CR2 is a complement activator and the covalent binding site for C3 during alternative pathway activation by Raji cells. , 1988, Journal of immunology.

[25]  V. Fischetti,et al.  Antiphagocytic activity of streptococcal M protein: selective binding of complement control protein factor H. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[26]  K. Joiner.  Complement evasion by bacteria and parasites. , 1988, Annual review of microbiology.

[27]  J. Lambris,et al.  A discontinuous factor H binding site in the third component of complement as delineated by synthetic peptides. , 1988, The Journal of biological chemistry.

[28]  Robert B Sim,et al.  The complete amino acid sequence of human complement factor H. , 1988, The Biochemical journal.

[29]  D. Kasper,et al.  Definition of a bacterial virulence factor: sialylation of the group B streptococcal capsule. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[30]  G. Nemerow,et al.  Hydrodynamic, electron microscopic, and ligand-binding analysis of the Epstein-Barr virus/C3dg receptor (CR2). , 1989, The Journal of biological chemistry.

[31]  J. Atkinson,et al.  Decay-accelerating factor and membrane cofactor protein. , 1990, Current topics in microbiology and immunology.

[32]  Robert B Sim,et al.  Molecular modelling of C3 and its ligands. , 1990, Current topics in microbiology and immunology.

[33]  S. Meri,et al.  Discrimination between activators and nonactivators of the alternative pathway of complement: regulation via a sialic acid/polyanion binding site on factor H. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[34]  G. R. Carson,et al.  Soluble human complement receptor type 1: in vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis. , 1990, Science.

[35]  S. Meri,et al.  Localization of the heparin-binding site on complement factor H. , 1991, The Journal of biological chemistry.

[36]  J. Atkinson,et al.  SEPARATION OF SELF FROM NON‐SELF IN THE COMPLEMENT SYSTEM: A ROLE FOR MEMBRANE COFACTOR PROTEIN AND DECAY ACCELERATING FACTOR , 1991, Clinical and experimental immunology.

[37]  N. Cooper.  Complement evasion strategies of microorganisms. , 1991, Immunology today.

[38]  Robert B Sim,et al.  Oligomeric domain structure of human complement factor H by X-ray and neutron solution scattering. , 1991, Biochemistry.

[39]  V. Fischetti,et al.  Streptococcal M protein. , 1991, Scientific American.

[40]  M. A. Wilson,et al.  Kinetic analysis of the amplification phase for activation and binding of C3 to encapsulated and nonencapsulated Cryptococcus neoformans , 1992, Infection and immunity.

[41]  E. Gotschlich,et al.  Gonococcal lipooligosaccharide sialylation prevents complement-dependent killing by immune sera , 1992, Infection and immunity.

[42]  R. Horstmann.  Target recognition failure by the nonspecific defense system: surface constituents of pathogens interfere with the alternative pathway of complement activation , 1992, Infection and immunity.

[43]  R. Discipio.  Ultrastructures and interactions of complement factors H and I. , 1992, Journal of immunology.

[44]  J. Cole,et al.  The sialylation of gonococcal lipopolysaccharide by host factors: a major impact on pathogenicity. , 1992, FEMS microbiology letters.

[45]  D. Gordon,et al.  Characterization of factor H binding to human polymorphonuclear leukocytes. , 1993, Journal of immunology.

[46]  G. Cornelis,et al.  Role of the YadA protein in prevention of opsonization of Yersinia enterocolitica by C3b molecules , 1993, Infection and immunity.

[47]  T. Kozel,et al.  Effects of strain variation, serotype, and structural modification on kinetics for activation and binding of C3 to Cryptococcus neoformans , 1993, Infection and immunity.

[48]  J. Dawes.  Interactions of heparins in the vascular environment. , 1993, Haemostasis.

[49]  P. Zipfel,et al.  Complement factor H and related proteins: an expanding family of complement-regulatory proteins? , 1994, Immunology today.

[50]  W. Schürch,et al.  Familial hemolytic-uremic syndrome and homozygous factor H deficiency. , 1994, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[51]  V. Nussenzweig,et al.  Role of sialic acid in the resistance of Trypanosoma cruzi trypomastigotes to complement. , 1994, Journal of Immunology.

[52]  L. Lopalco,et al.  HIV glycoprotein 41 and complement factor H interact with each other and share functional as well as antigenic homology. , 1995, AIDS research and human retroviruses.

[53]  E. Fosse,et al.  A new model for evaluation of biocompatibility: combined determination of neoepitopes in blood and on artificial surfaces demonstrates reduced complement activation by immobilization of heparin. , 1995, Artificial organs.

[54]  P. Zipfel,et al.  Mapping of the complement regulatory domains in the human factor H-like protein 1 and in factor H1. , 1995, Journal of immunology.

[55]  R. Horstmann,et al.  Location of the complement factor H binding site on streptococcal M6 protein , 1995, Infection and immunity.

[56]  D. Lublin,et al.  Identification of complement regulatory domains in human factor H. , 1995, Journal of immunology.

[57]  J. H. Jansen,et al.  Hereditary porcine membranoproliferative glomerulonephritis type II is caused by factor H deficiency. , 1995, The Journal of clinical investigation.

[58]  M. Dierich,et al.  Efficient destruction of human immunodeficiency virus in human serum by inhibiting the protective action of complement factor H and decay accelerating factor (DAF, CD55) , 1996, The Journal of experimental medicine.

[59]  J. Atkinson,et al.  Control of the complement system. , 1996, Advances in immunology.

[60]  T. Simmen,et al.  IgM polymerization inhibits the Golgi-mediated processing of the mu-chain carboxy-terminal glycans. , 1996, Molecular immunology.

[61]  M. Pangburn,et al.  Identification of three physically and functionally distinct binding sites for C3b in human complement factor H by deletion mutagenesis. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[62]  R. Locksley,et al.  The Instructive Role of Innate Immunity in the Acquired Immune Response , 1996, Science.

[63]  M. Pangburn,et al.  Localization by site-directed mutagenesis of the site in human complement factor H that binds to Streptococcus pyogenes M protein , 1997, Infection and immunity.

[64]  D. Fearon.  Seeking wisdom in innate immunity , 1997, Nature.

[65]  W. Ellis,et al.  Clinical evaluation of the BTA TRAK assay and comparison to voided urine cytology and the Bard BTA test in patients with recurrent bladder tumors. The Multi Center Study Group. , 1997, Urology.

[66]  P. Zipfel,et al.  The Human Factor H-related Protein 4 (FHR-4) , 1997, The Journal of Biological Chemistry.

[67]  S. Ram,et al.  A Novel Sialic Acid Binding Site on Factor H Mediates Serum Resistance of Sialylated Neisseria gonorrhoeae , 1998, The Journal of experimental medicine.

[68]  Binding of Complement Factor H to Loop 5 of Porin Protein 1A: A Molecular Mechanism of Serum Resistance of Nonsialylated Neisseria gonorrhoeae , 1998 .

[69]  R. Discipio,et al.  Human polymorphonuclear leukocytes adhere to complement factor H through an interaction that involves alphaMbeta2 (CD11b/CD18). , 1998, Journal of immunology.

[70]  S. Meri,et al.  Each of the three binding sites on factor H interacts with a distinct site on C3b , 1998 .

[71]  V. Fischetti,et al.  M Protein of the Group A StreptococcusBinds to the Seventh Short Consensus Repeat of Human Complement Factor H , 1998, Infection and Immunity.

[72]  P. Zipfel,et al.  Identification of the second heparin-binding domain in human complement factor H. , 1998, Journal of immunology.

[73]  M. Carroll,et al.  The role of complement and complement receptors in induction and regulation of immunity. , 1998, Annual review of immunology.

[74]  R. Kinders,et al.  Complement factor H or a related protein is a marker for transitional cell cancer of the bladder. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[75]  E. Johnsson,et al.  Identification of a domain in human factor H and factor H-like protein-1 required for the interaction with streptococcal M proteins. , 1998, Journal of immunology.

[76]  A. J. Mcadams,et al.  The alternative pathway C3 convertase and glomerular deposits , 1999, Pediatric Nephrology.

[77]  C. Mold,et al.  Regulation of complement activation by C-reactive protein. , 1999, Immunopharmacology.

[78]  R. Würzner,et al.  Evasion of pathogens by avoiding recognition or eradication by complement, in part via molecular mimicry. , 1999, Molecular immunology.

[79]  S. Meri,et al.  The factor H protein family. , 1999, Immunopharmacology.

[80]  L. Smith,et al.  Complement systems in invertebrates. The ancient alternative and lectin pathways. , 1999, Immunopharmacology.

[81]  K. Skjødt,et al.  The structural basis for complement receptor type 2 (CR2, CD21)‐mediated alternative pathway activation of complement: studies with CR2 deletion mutants and vaccinia virus complement‐control protein‐CR2 chimeras , 1999, European journal of immunology.

[82]  V. Sheffield,et al.  Complement factor H gene mutation associated with autosomal recessive atypical hemolytic uremic syndrome. , 1999, American journal of human genetics.

[83]  S. Meri,et al.  Factor H and disease: a complement regulator affects vital body functions. , 1999, Molecular immunology.

[84]  F C Kafatos,et al.  Phylogenetic perspectives in innate immunity. , 1999, Science.

[85]  S. Meri,et al.  Regulation of complement activation by C-reactive protein: targeting the complement inhibitory activity of factor H by an interaction with short consensus repeat domains 7 and 8-11. , 1999, Journal of immunology.

[86]  S. Meri,et al.  Each of the three binding sites on complement factor H interacts with a distinct site on C3b. , 2000, The Journal of biological chemistry.